- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04223869
IL-34 Levels in Various Types of Periodontitis
Critical Role of Interleukin-34 in Gingival Crevicular Fluid as a Potential Markers of Inflammation in Patients With Periodontitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A novel cytokine interleukin 34 (IL-34) is a second possible functional ligand of macrophage colony-stimulating factor-1 receptor (CSF-1R). IL-34 is secreted in different tissues including: heart, brain, lung, liver, kidney, thymus, testes, ovary, small intestine, prostate, colon and spleen . IL-34 shares vital functions of macrophage colony-stimulating factor -1(CSF-1), and manage myeloid cell survival, differentiation and proliferation. It is produced by synovial fluid, gingival fibroblast and human adipose tissue, and is controlled by the transcription factor RANK and activation of c-Jun N-terminal kinase (CJNK). Additionally, the pro-inflammatory cytokines tumornecrosis factor-alfa (TNF-α) and interleukin-1beta (IL-1β) arrange IL-34 release from gingival fibroblasts, by a mechanism including nuclear factor -kB (NF-kB) and mitogen activated protein kinase (MAPK).The targeting CSF-1 merely is not adequate to inhibit the effect via CSF-1R. Moreover, neither RANKL nor IL-34 solely can cause osteoclast formation which suggests that IL-34 is required but not enough. IL-34 plays a crucial role in RANKL-induced osteoclastogenesis; the osteoclasts differentiation is mediated by the same way with CSF-1.
Several studies evaluated the role of IL-34 in the pathogenesis of chronic periodontitis (CP). To the best of our knowledge, any of these studies reported the relationship between GCF IL-34 level and GCF RANKL/OPG ratio in other types of periodontitis before and after non-surgical periodontal therapy. This study highlights the influence of IL-34 in the pathogenesis of Chronic Periodontitis (CP) and Aggressive Periodontitis (AgP).
The objective of this study is to 1) identification of the impact of IL-34 on the pathogenesis of periodontal disease and determine whether any relationship among the existing levels of GCF IL-34 and GCF RANKL, OPG and RANKL/OPG ratio, as a mediator of bone resorption 2) analysis of the impact of non-surgical periodontal treatment on GCF IL-34 levels in patients with CP and AgP and 3) to correlate between biochemical markers and clinical recordings.
The study included 60 subjects: 20 who were periodontally healthy (CTRL), 20 with chronic periodontitis (CP)and 20 with aggressive periodontitis (AgP). Patients with periodontitis were treated with non-surgical periodontal therapy. GCF sampling procedures and clinical periodontal measures were investigated at the baseline and 6 weeks after treatment. Levels of IL-34, RANKL and OPG were analyzed with Enzyme-linked immunosorbent assay (ELISA).
Participants were periodontally assessed at baseline and after non-surgical periodontal therapy in accordance with the following criteria; plaque index (PI)(Silness and Loe, 1964), GI(Loe and Silness, 1963), PPD, clinical attachment level (CAL) and BOP (judged positive if it developed within 15 s following contact). Full-mouth periapical radiographs were used to determine the periodontal bone loss.The clinical measurement were taken in millimeters by a single calibrated examiner (ŞBD), who was blinded to the whole study composition, from six locations of each tooth (mesio-buccal, disto-buccal, mid-buccal, mesiolingual, disto-lingual, and mid-lingual), by the use of a periodontal probe (Hu-Friedy, Chicago, IL, USA).
Two sites per participant were selected to collect GCF for each group. GCF samples were collected from the mesiobuccal or distobuccal sites of single-rooted teeth. The sample areas were isolated with cotton rolls, saliva contamination was ensured, all supragingival plaque was eliminated by sterile curette and it was slightly air dried. The paper strips were inserted within the crevice until resistance was encountered and then allowed to remain in place for 30 seconds. The amount of GCF on the strips was measured by weighing the collected liquid. The strips were placed into closed and numbered plastic eppendorf tubes. The liquid was weighed again, immediately after collection, to take into account evaporation. The samples consisting of saliva and blood were discarded from the study. Two available for use samples from per individual were merged to make a singular sample and instantly insert in a singular Eppendorf tube and freezed at _80°C until aftertime evaluation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- CP group included 20 patients, ≥ 35 years of age, and this category was displayed as a minimum of six teeth available clinical attachment loss (AL) and pocket probing depth (PPD) ≥ 5mm. These teeth exhibited positive bleeding on probing (BOP) across a minumum 2 separate quadrants and bone loss affecting >30 % of available teeth on clinical and radiographic inspection. The gingival index (GI) score for indications of inflammation (red color and edema of the gingival margin) was >1 for the CP group.
- AgP group included 20 patients, <35 years of age, and cases showed PPD≥ 5mm with at least six teeth and radiographic evidence of alveolar bone loss. At least three of these six teeth with PPD ≥ 5 mm were not molars or incisors. These patients showed severe periodontal tissue devastation and decrease of periodontal support conflicting with age and plaque levels.
- Control group included 20 participants and they presented PPD ≤ 3mm, GI=0 (nonavailable of clinical inflammation), absence of alveolar bone loss (e.g., distance between the cemento-enamel junction and the bone crest was <3mm in> 95% of proximal tooth sites).
- All participants had minimum 20 teeth and their overall systematic health
Exclusion Criteria:
- lactation
- pregnancy
- current and ex-smoking habits
- undergone nonsurgical periodontal therapy and prescription of antibiotics or non-steroidal anti-inflammatory medication within the previous 6 months or surgical periodontal treatment within the preceding year
- postmenopause
- systemic conditions such as; diabetes mellitus, cancer, cardiovascular and respiratory diseases, rheumatoid arthritis, osteoporosis, or immunologic disorders, that might cause progress of periodontal disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: periodontally healthy group
Control
|
|
Active Comparator: Chronic Periodontitis
non-surgical periodontal treatment was performed
|
scaling and root planing were performed
|
Active Comparator: Aggressive Periodontitis
non-surgical periodontal treatment was performed
|
scaling and root planing were performed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
gingival crevicular fluid IL-34 level
Time Frame: 6th week
|
gingival crevicular fluid IL-34 levels change from baseline to at 6th week
|
6th week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gingival crevicular fluid RANKL level
Time Frame: 6th week
|
change of gingival crevicular fluid RANKL levels from baseline at 6th weeks
|
6th week
|
Gingival crevicular fluid OPG level
Time Frame: 6th week
|
change of gingival crevicular fluid OPG levels from baseline at 6th weeks
|
6th week
|
Plaque index
Time Frame: 6th week
|
oral hygiene score
|
6th week
|
Gingival index
Time Frame: 6th week
|
gingival inflammation score
|
6th week
|
bleeding on probing
Time Frame: 6th week
|
deemed positive if it occurred within 15 seconds after probing
|
6th week
|
clinical attachment level
Time Frame: 6th week
|
distance between the cemento-enamel junction to the deepest point of periodontal pocket
|
6th week
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Figen Öngöz Dede, PhD, DDS, T.C. ORDU ÜNİVERSİTESİ
- Study Chair: Şeyma Bozkurt Doğan, PhD, DDS, Ankara Yildirim Beyazıt University
- Principal Investigator: Umut Ballı, Phd, DDS, Bülent Ecevit University Faculty of Dentistry
- Principal Investigator: Erdim Sertoğlu, PhD, DDS, Ankara Sağlık Bilimleri University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-106-03/06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aggressive Periodontitis
-
Asem Mohammed Kamel AliCompletedMolar-incisor Pattern Grade C Periodontitis ( Localized Aggressive Periodontitis) | Generalized Grade C Periodontitis (Generalized Aggressive Periodontitis)Egypt
-
Tokat Gaziosmanpasa UniversityCompletedChronic Periodontitis | Localized Aggressive PeriodontitisTurkey
-
Universidade Estadual Paulista Júlio de Mesquita...UnknownAggressive Periodontitis, Generalized
-
Medical University of WarsawUnknown
-
Kocaeli UniversityUnknownChronic Periodontitis | Generalized Aggressive Periodontitis
-
Tanta UniversityActive, not recruitingLocalized Aggressive PeriodontitisEgypt
-
Kocaeli UniversityCompletedAggressive Periodontitis | Generalized Aggressive PeriodontitisTurkey
-
Marmara UniversityCompletedGeneralized Aggressive Periodontitis
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedAggressive Periodontitis, Generalized
-
Peking UniversityCompletedAggressive Periodontitis, GeneralizedChina
Clinical Trials on non-surgical periodontal treatment
-
Necmettin Erbakan UniversityNot yet recruiting
-
University of CataniaRecruitingAtherosclerosis | Endothelial Dysfunction | Peri-Implantitis | Peri-implant MucositisItaly
-
Malmö UniversitySkane University Hospital; Swedish Dental Service OrganisationRecruitingHeart Diseases | Sepsis | Periodontal Diseases | BacteremiaSweden
-
University of Turin, ItalyCompletedPeriodontitis | Dysbiosis | Intestinal DiseaseItaly
-
Gazi UniversityCompletedSmoking | Periodontitis | Periodontal Diseases | Smoking, TobaccoTurkey
-
University Hospital, Strasbourg, FranceTerminated
-
Universidade Estadual Paulista Júlio de Mesquita...LabviValeCompletedType 2 Diabetes Mellitus With Periodontal DiseaseBrazil
-
National University Health System, SingaporeCompletedPeri-Implantitis | Dental Plaque | Peri-implant MucositisSingapore
-
Mustafa Kemal UniversityCompleted